Matthew Robson
Research Fellow
Last active: 10/19/2015


None provided


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Platelet response to increased aspirin dose in patients with persistent platelet aggregation while treated with aspirin 81 mg. Gengo F, Westphal ES, Rainka MM, Janda M, Robson MJ, Hourihane JM, Bates V (2016) J Clin Pharmacol 56(4): 414-21
    › Primary publication · 26239393 (PubMed)
  2. Role of sigma-1 receptors in neurodegenerative diseases. Nguyen L, Lucke-Wold BP, Mookerjee SA, Cavendish JZ, Robson MJ, Scandinaro AL, Matsumoto RR (2015) J Pharmacol Sci 127(1): 17-29
    › Primary publication · 25704014 (PubMed)
  3. Altering endoplasmic reticulum stress in a model of blast-induced traumatic brain injury controls cellular fate and ameliorates neuropsychiatric symptoms. Logsdon AF, Turner RC, Lucke-Wold BP, Robson MJ, Naser ZJ, Smith KE, Matsumoto RR, Huber JD, Rosen CL (2014) Front Cell Neurosci : 421
    › Primary publication · 25540611 (PubMed) · PMC4261829 (PubMed Central)
  4. Sigma receptors as potential therapeutic targets for neuroprotection. Nguyen L, Kaushal N, Robson MJ, Matsumoto RR (2014) Eur J Pharmacol : 42-7
    › Primary publication · 25261035 (PubMed) · PMC4454619 (PubMed Central)
  5. Methamphetamine-induced toxicity: an updated review on issues related to hyperthermia. Matsumoto RR, Seminerio MJ, Turner RC, Robson MJ, Nguyen L, Miller DB, O'Callaghan JP (2014) Pharmacol Ther 144(1): 28-40
    › Primary publication · 24836729 (PubMed) · PMC4700537 (PubMed Central)
  6. Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan. Nguyen L, Robson MJ, Healy JR, Scandinaro AL, Matsumoto RR (2014) PLoS One 9(2): e89985
    › Primary publication · 24587167 (PubMed) · PMC3938562 (PubMed Central)
  7. SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation. Robson MJ, Turner RC, Naser ZJ, McCurdy CR, O'Callaghan JP, Huber JD, Matsumoto RR (2014) Exp Neurol : 180-9
    › Primary publication · 24508558 (PubMed) · PMC4241368 (PubMed Central)
  8. Sigma (σ) receptors as potential therapeutic targets to mitigate psychostimulant effects. Matsumoto RR, Nguyen L, Kaushal N, Robson MJ (2014) Adv Pharmacol : 323-86
    › Primary publication · 24484982 (PubMed)
  9. Neuroprotective targets through which 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a sigma receptor ligand, mitigates the effects of methamphetamine in vitro. Kaushal N, Robson MJ, Rosen A, McCurdy CR, Matsumoto RR (2014) Eur J Pharmacol : 193-203
    › Primary publication · 24380829 (PubMed) · PMC3993961 (PubMed Central)
  10. Modeling clinically relevant blast parameters based on scaling principles produces functional & histological deficits in rats. Turner RC, Naser ZJ, Logsdon AF, DiPasquale KH, Jackson GJ, Robson MJ, Gettens RT, Matsumoto RR, Huber JD, Rosen CL (2013) Exp Neurol : 520-9
    › Primary publication · 23876514 (PubMed)
  11. σ Receptor antagonist attenuation of methamphetamine-induced neurotoxicity is correlated to body temperature modulation. Robson MJ, Seminerio MJ, McCurdy CR, Coop A, Matsumoto RR (2013) Pharmacol Rep 65(2): 343-9
    › Primary publication · 23744418 (PubMed)
  12. SN79, a sigma receptor ligand, blocks methamphetamine-induced microglial activation and cytokine upregulation. Robson MJ, Turner RC, Naser ZJ, McCurdy CR, Huber JD, Matsumoto RR (2013) Exp Neurol : 134-42
    › Primary publication · 23631864 (PubMed) · PMC3742718 (PubMed Central)
  13. Repetitive traumatic brain injury and development of chronic traumatic encephalopathy: a potential role for biomarkers in diagnosis, prognosis, and treatment? Turner RC, Lucke-Wold BP, Robson MJ, Omalu BI, Petraglia AL, Bailes JE (2012) Front Neurol : 186
    › Primary publication · 23335911 (PubMed) · PMC3547169 (PubMed Central)
  14. Pharmacological evaluation of SN79, a sigma (σ) receptor ligand, against methamphetamine-induced neurotoxicity in vivo. Kaushal N, Seminerio MJ, Robson MJ, McCurdy CR, Matsumoto RR (2013) Eur Neuropsychopharmacol 23(8): 960-71
    › Primary publication · 22921523 (PubMed) · PMC3748261 (PubMed Central)
  15. Sigma receptor antagonists attenuate acute methamphetamine-induced hyperthermia by a mechanism independent of IL-1β mRNA expression in the hypothalamus. Seminerio MJ, Robson MJ, McCurdy CR, Matsumoto RR (2012) Eur J Pharmacol 691(1-3): 103-9
    › Primary publication · 22820108 (PubMed) · PMC3726051 (PubMed Central)
  16. Sigma-1 receptors: potential targets for the treatment of substance abuse. Robson MJ, Noorbakhsh B, Seminerio MJ, Matsumoto RR (2012) Curr Pharm Des 18(7): 902-19
    › Primary publication · 22288407 (PubMed)
  17. CM156, a sigma receptor ligand, reverses cocaine-induced place conditioning and transcriptional responses in the brain. Xu YT, Robson MJ, Szeszel-Fedorowicz W, Patel D, Rooney R, McCurdy CR, Matsumoto RR (2012) Pharmacol Biochem Behav 101(1): 174-80
    › Primary publication · 22234290 (PubMed) · PMC3726055 (PubMed Central)
  18. Synthesis and pharmacological characterization of a novel sigma receptor ligand with improved metabolic stability and antagonistic effects against methamphetamine. Seminerio MJ, Robson MJ, Abdelazeem AH, Mesangeau C, Jamalapuram S, Avery BA, McCurdy CR, Matsumoto RR (2012) AAPS J 14(1): 43-51
    › Primary publication · 22183188 (PubMed) · PMC3291180 (PubMed Central)
  19. AC927, a σ receptor ligand, blocks methamphetamine-induced release of dopamine and generation of reactive oxygen species in NG108-15 cells. Kaushal N, Elliott M, Robson MJ, Iyer AK, Rojanasakul Y, Coop A, Matsumoto RR (2012) Mol Pharmacol 81(3): 299-308
    › Primary publication · 22101517 (PubMed) · PMC3286303 (PubMed Central)
  20. Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo. Robson MJ, Elliott M, Seminerio MJ, Matsumoto RR (2012) Eur Neuropsychopharmacol 22(4): 308-17
    › Primary publication · 21911285 (PubMed)
  21. Synthesis and pharmacological evaluation of indole-based sigma receptor ligands. Mésangeau C, Amata E, Alsharif W, Seminerio MJ, Robson MJ, Matsumoto RR, Poupaert JH, McCurdy CR (2011) Eur J Med Chem 46(10): 5154-61
    › Primary publication · 21899931 (PubMed) · PMC3272488 (PubMed Central)
  22. Synthesis and pharmacological evaluation of 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a cocaine antagonist, in rodents. Kaushal N, Robson MJ, Vinnakota H, Narayanan S, Avery BA, McCurdy CR, Matsumoto RR (2011) AAPS J 13(3): 336-46
    › Primary publication · 21494909 (PubMed) · PMC3160158 (PubMed Central)
  23. Sigma receptors: potential targets for a new class of antidepressant drug. Fishback JA, Robson MJ, Xu YT, Matsumoto RR (2010) Pharmacol Ther 127(3): 271-82
    › Primary publication · 20438757 (PubMed) · PMC3993947 (PubMed Central)
  24. Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. Gengo FM, Rainka M, Robson M, Gengo MF, Forrest A, Hourihane M, Bates V (2008) J Clin Pharmacol 48(3): 335-43
    › Primary publication · 18223144 (PubMed)
  25. Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. Gengo FM, Rubin L, Robson M, Rainka M, Gengo MF, Mager DE, Bates V (2008) J Clin Pharmacol 48(1): 117-22
    › Primary publication · 18094224 (PubMed)